Calamos Advisors’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Calamos Advisors’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-250,000	Closed	-$2.47M	–	1486
2022 Q2	$2.47M	Hold	250,000	–	–	0.01%	879
2022 Q1	$2.47M	Hold	250,000	–	–	0.01%	882
2021 Q4	$2.5M	Hold	250,000	–	–	0.01%	859
2021 Q3	$2.5M	Hold	250,000	–	–	0.01%	745
2021 Q2	$2.51M	Hold	250,000	–	–	0.01%	686
2021 Q1	$2.46M	Buy	+250,000	New	+$2.5M	0.01%	672

Other funds holding IBER.U

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Calamos Advisors's IBER.U Position: Q3 2022 in Review

Calamos Advisors sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q3 2022, closing a stake of 250,000 shares — an estimated $2.47M sold.

Calamos Advisors first reported a position in IBER.U in Q1 2021 and held it in 6 quarters. The position peaked at $2.51M in Q2 2021. 13 funds tracked by Wall St. Rank hold IBER.U as of Q3 2022.

Calamos Advisors reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q3 2022 after selling out during the quarter.
Calamos Advisors sold 250,000 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q3 2022, an estimated $2.47M.
Calamos Advisors first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 6 quarters.
Calamos Advisors's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $2.51M in Q2 2021.
13 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q3 2022.

Based on Calamos Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.